14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.61 $7.24 Friday, 3rd May 2024 AFMD stock ended at $5.42. This is 2.26% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 8.04% from a day low at $5.10 to a day high of $5.51.
90 days $4.25 $7.24
52 weeks $2.24 $11.10

Historical Affimed N.V. prices

Date Open High Low Close Volume
May 11, 2021 $89.50 $94.25 $88.80 $93.80 191 057
May 10, 2021 $97.00 $97.00 $91.50 $93.80 156 026
May 07, 2021 $97.50 $101.10 $96.97 $98.10 172 023
May 06, 2021 $102.90 $103.20 $93.30 $97.00 272 504
May 05, 2021 $105.80 $106.30 $101.70 $103.20 131 654
May 04, 2021 $107.60 $108.00 $103.60 $105.60 137 499
May 03, 2021 $107.00 $112.20 $106.60 $109.20 145 651
Apr 30, 2021 $109.40 $112.60 $105.90 $106.90 134 690
Apr 29, 2021 $114.20 $115.20 $109.10 $110.70 127 533
Apr 28, 2021 $111.10 $116.50 $110.00 $114.00 242 341
Apr 27, 2021 $114.40 $115.80 $108.81 $112.20 192 977
Apr 26, 2021 $112.80 $117.40 $109.10 $113.70 270 946
Apr 23, 2021 $104.69 $113.80 $104.00 $110.40 371 364
Apr 22, 2021 $100.70 $106.70 $99.20 $104.20 260 543
Apr 21, 2021 $89.90 $102.75 $88.44 $100.45 284 148
Apr 20, 2021 $94.70 $96.80 $87.20 $89.60 236 386
Apr 19, 2021 $92.80 $98.40 $92.20 $96.20 205 410
Apr 16, 2021 $95.60 $96.00 $91.50 $95.10 230 682
Apr 15, 2021 $98.60 $100.50 $90.60 $94.80 548 267
Apr 14, 2021 $97.60 $107.90 $96.70 $103.30 595 592
Apr 13, 2021 $99.40 $105.40 $97.10 $98.90 775 519
Apr 12, 2021 $101.10 $101.20 $92.80 $96.50 748 529
Apr 09, 2021 $102.70 $107.00 $92.30 $97.40 7 959 461
Apr 08, 2021 $79.40 $80.90 $77.30 $78.90 184 728
Apr 07, 2021 $79.70 $80.90 $77.12 $78.00 109 702
Click to get the best stock tips daily for free!

About Affimed N.V.

Affimed N.V. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT